Back to top
more

McKesson (MCK)

(Real Time Quote from BATS)

$597.48 USD

597.48
134,312

+7.49 (1.27%)

Updated Jul 25, 2024 11:04 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (105 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Edwards Lifesciences (EW) Debuts SAPIEN 3 Ultra RESILIA Valve

by Zacks Equity Research

Edwards Lifesciences' (EW) SAPIEN 3 Ultra RESILIA valve combines its breakthrough RESILIA tissue technology with the SAPIEN 3 Ultra transcatheter aortic heart valve.

Swayta Shah headshot

3 Stocks With Upgraded Broker Ratings for Robust Returns

by Swayta Shah

As brokers have a deeper understanding of stocks, one must follow rating upgrades before investing. We select BJ, MCK and CRS as these have seen rating upgrades recently.

Here's Why You Should Hold on to Ecolab (ECL) Stock Now

by Zacks Equity Research

Investors continue to be optimistic about Ecolab (ECL) owing to its strong business.

Globus Medical (GMED) Gains Market Share, Cost Woes Stay

by Zacks Equity Research

Globus Medical (GMED) U.S. sales increase, driven by competitive rep conversions and robotic pull-through.

Here is Why Growth Investors Should Buy McKesson (MCK) Now

by Zacks Equity Research

McKesson (MCK) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Here's Why You Should Retain West Pharmaceutical (WST) Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.

Charles River (CRL) to Support Cure AP-4's Clinical Trials

by Zacks Equity Research

Charles River's (CRL) manufacturing collaboration with Cure AP-4 will support the latter's Phase I/II gene therapy trials for a rare neurodegenerative disorder.

Here's Why You Should Retain Cardinal Health (CAH) Stock Now

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, the cost of products continues to rise.

Zimmer Biomet (ZBH) Procedure Recovery Strong, Margin Woe Stays

by Zacks Equity Research

Zimmer Biomet's (ZBH) recently completed spin-off of the non-core dental and spine business is expected to prove strategic.

Here's Why Investors Should Retain Abbott (ABT) Stock Now

by Zacks Equity Research

Strong results across the EPD, diagnostics and medical devices businesses are driving Abbott's (ABT) top line.

Abbott (ABT) Debuts Amplatzer Talisman System in Europe

by Zacks Equity Research

Abbott's (ABT) Amplatzer Talisman PFO Occlusion System will enable doctors across Europe to treat people experiencing a patent foramen ovale-associated stroke.

Accuray's (ARAY) Latest Collaboration to Improve Patient Care

by Zacks Equity Research

Accuray (ARAY) partners with Genolier Innovation Hub to unite companies from the MedTech, pharma and biosciences sectors with physicians and scientists for better patient outcomes.

Glaukos (GKOS) Up on Positive Glaucoma Study Data on iDose TR

by Zacks Equity Research

Glaukos' (GKOS) targeted injectable implant candidate, iDose TR, achieves a non-inferior reduction in IOP in patients with open-angle glaucoma versus daily treatment with timolol.

Quest Diagnostics (DGX) Stock Gains on EUA for Monkeypox Test

by Zacks Equity Research

According to Quest Diagnostics (DGX), this test can differentiate monkeypox viral DNA from other non-variola orthopoxviruses in a specimen, helping to enable a faster final diagnosis.

Edward Lifesciences (EW) Gains From New Products Amid Cost Woe

by Zacks Equity Research

Edwards Lifesciences (EW) expects full-year 2022 underlying sales to grow on the back of strength in demand for products used in more intense surgeries.

    Reasons to Retain Merit Medical (MMSI) Stock in Your Portfolio

    by Zacks Equity Research

    Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.

      Boston Scientific's (BSX) WATCHMAN FLX to Offer DAPT in the US

      by Zacks Equity Research

      Boston Scientific (BSX) to offer updated labeling for WATCHMAN FLX device after receiving FDA approval.

      Here's Why You Should Hold on to Allscripts (MDRX) Stock Now

      by Zacks Equity Research

      Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances.

      HealthEquity (HQY) Q2 Earnings Lag Estimates, Margins Down

      by Zacks Equity Research

      HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in majority of its segments, in the second quarter of fiscal 2023.

      Derek Lewis headshot

      Invest Like Warren Buffett With These 3 Stocks

      by Derek Lewis

      The Oracle of Omaha has been on the offensive in 2022, recognizing value in a challenging market.

      Neogen (NEOG) Finalizes Food Safety Business Merger With 3M

      by Zacks Equity Research

      The combination of Neogen (NEOG) and 3M's Food Safety division will capitalize on the ongoing growth trends in sustainability, food safety and supply chain integrity.

      SmileDirectClub (SDC) Faces Low Aligner Shipment, Margin Woe

      by Zacks Equity Research

      The ongoing macroeconomic challenges continue to impact SmileDirectClub's (SDC) core demographic and business spending.

      Here's Why You Should Retain Change Healthcare (CHNG) Stock

      by Zacks Equity Research

      Change Healthcare (CHNG) continues to benefit from strategic deals. However, intense competition remains a woe.

      CVS Health (CVS) to Buy Signify Health, Grow in Home Healthcare

      by Zacks Equity Research

      According to CVS Health (CVS), Signify Health, as a leading healthcare platform, will play a critical role in advancing the company's healthcare services strategy.

      Baxter (BAX) Novum IQ SYR's FDA Clearance Boosts Patient Care

      by Zacks Equity Research

      Latest regulatory approval for Baxter's (BAX) Novum IQ SYR is expected to provide safe and accurate infusions for vulnerable patients.